Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1Phase 1 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1

Conditions

Colorectal Neoplasms 36Breast Neoplasms 29Pancreatic Neoplasms 20Rectal Neoplasms 17Stomach Neoplasms 16Neoplasm Metastasis 16Neoplasms 12Esophageal Neoplasms 8Triple Negative Breast Neoplasms 7Colonic Neoplasms 7Colorectal Cancer Metastatic 6Carcinoma, Non-Small-Cell Lung 5Squamous Cell Carcinoma of Head and Neck 4Brain Neoplasms 4Adenocarcinoma 4Head and Neck Neoplasms 3Gastrointestinal Neoplasms 3Biliary Tract Neoplasms 3Bile Duct Neoplasms 3Advanced Solid Tumors 3Sarcoma 2Parkinson Disease 4, Autosomal Dominant Lewy Body 2Ovarian Neoplasms 2Melanoma 2Lymphoma, Non-Hodgkin 2Liver Neoplasms 2Diabetes Mellitus, Insulin-Dependent, 12 2Cholangiocarcinoma 2Carcinoma, Renal Cell 2Carcinoma, Hepatocellular 2

Interventions

vandetanib 3selpercatinib 2rovalpituzumab tesirine 1pralsetinib 1Peripheral Blood Stem Cell Transplantation 1Indium 1Imatinib Mesylate 1Filgrastim 1Doxorubicin 1Dexamethasone 1Dacarbazine 1Capecitabine 1Calcium Aluminosilicate 1Bortezomib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Carcinoma, Medullary × Capecitabine × Clear all
NCT00354523 2014-12-17

Imatinib in Combination With Dacarbazine and Capecitabine in Medullary Thyroid Carcinoma

M.D. Anderson Cancer Center

Phase 1/2 Terminated
21 enrolled
Head & Neck

Thyroid Neoplasms, Carcinoma, Medullary

Data powered by HemOnc (CC BY 4.0) Colophon âš¡